Patient perceptions of multiple sclerosis and its treatment

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 263-273

  de Seze, Jérôme ^a   Borgel, Florent ^b   Brudon, Frédérique ^c  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b University Medical Center   (France)

^c Clinique du Tonkin   (France)

Author keywords

Multiple sclerosis; Patient adherence; Quality of life

Indexed keywords

BETA INTERFERON; GLATIRAMER;

ADULT; AGED; ARTICLE; AWARENESS; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FRANCE; GASTROINTESTINAL DISEASE; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTIPLE SCLEROSIS; MYALGIA; NEUROLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PERCEPTION; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; SIDE EFFECT; SKIN MANIFESTATION; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 84878828527     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S27038     Document Type: Article

References (24)

1. Wu N, Minden SL, Hoaglin DC, Hadden L, Frankel D. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm. 2007;30(3):233-267.
2. Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmaco Economics. 2009;27(8):681-691.
3. Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci. 2009;277 Suppl 1:S37-S41.
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-294.
5. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-1276.
6. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.
7. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285.
8. Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler. 2006;12(3):309-320.
9. Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255 Suppl 6:87-92.
10. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol. 2005;12(6):425-431.
11. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler. 2005;11(1):46-50.
12. Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry. 2003;74(12):1689-1692.
13. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61(4):551-554.
14. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1-9.
15. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10(9):225.
16. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1): 44-47.
17. Traboulsee A, Uitdehaag BMJ, Kappos L, et al. Measures of treatment adherence as prognostic factors for long-term outcomes in relapsingremitting multiple sclerosis. Mult Scler. 2010;16 Suppl 10:S165.
18. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89-100.
19. Kleinman NL, Beren IA, Rajagopalan K, Brook RA. Medication adherence with disease-modifying treatments for multiple sclerosis among US employees. J Med Econ. 2010;13(4):633-640.
20. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17(6):565-576.
21. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69-77.
22. Arroyo E, Grau C, Ramo C, Parra J, Sanchez-Solino O. Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results [Estudio global de adherencia a los tratamientos inmunomoduladores en pacientes con esclerosis múltiple remitente recidivante: resultados a 2 años]. Neurologia. 2010;25(7):435-442. [Spanish.]
23. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11(3):306-309.
24. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ. 1997;314(7094):1580-1583.